Saturday 17 October 2026 Export RDY’s income statement to Excel — free account

Dr. Reddy's Laboratories Ltd

RDY Healthcare Drug Manufacturers Specialty & Generic

Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025. In the quarter to June 2026, revenue fell 14.4%, EPS fell 70.0%, free cash flow fell 143.4% and total debt rose 34.0%, each against the same quarter a year earlier.

13.05 0.15 +1.16%

Follow RDY

Alert me

Market cap: $10.7B
P/E: 32.9×
Fwd P/E: 24.3×
Dividend yield: 0.00%
F-score: 4/9
Altman Z: 5.26
Beneish M: −2.59
Dividend safety: 74/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 10,740.00

Revenue 3,436.00

Net Income 334.00

Free Cash Flow 139.00

Net Debt (105.00)

Current Ratio 1.90

Debt/Equity 0.19

P/E ratio 32.86

Fwd P/E 24.30

P/S ratio 2.98

P/B ratio 2.50

Past 5Y EPS Growth 11.86%

This Y EPS Growth (17.76%)

Next Y EPS Growth 32.52%

Next Y revenue growth 6,726.14%

Next 5Y EPS Growth 10.03%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 68.56%

10-year low 10-year high

P/S against its own 10 years 31.48%

10-year low 10-year high

P/B against its own 10 years 3.61%

10-year low 10-year high

EV/Sales against its own 10 years 27.87%

10-year low 10-year high

EV/FCF against its own 10 years 83.67%

10-year low 10-year high

Dividends

Payout Ratio 0.00

Annual Dividend Rate 0.00

Annual Dividend Yield 0.00%

	total	individual payouts
2029	Powerpack
2028	Powerpack
2027	Powerpack
2026	Powerpack
2025	6.85	0.09
2024	0.10	0.10
2023	0.58	0.49 0.10
2022	0.08	0.08
2021	0.34	0.34
2020	0.07	0.07
2019	0.06	0.06
2018	0.06	0.06
2017	0.06	0.06
2016	0.06	0.06

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	979	685	938	865
Receivables	963	1,058	1,079	1,062
Inventory	763	832	816	850
Other	271	353	386	384
	2,976	2,928	3,219	3,162

	2024	2025	2026	Q'26
Payables	371	417	356	396
ST’ Debt	169	455	694	634
Other	586	620	691	586
	1,152	1,527	1,787	1,661

Compound Annual Growth %

	10y	5y	3y
Sales	4.37%	6.66%	6.16%
Cash Flow	(0.26%)	4.46%	(5.36%)
Earnings	4.21%	14.08%	(5.94%)
Book Value	7.67%	11.37%	12.99%

Revenue $m

	Jun	Sep	Dec	Mar	Year
’26	853	—	—	—	—
’26	997	1,013	977	593	3,580
’25	921	954	986	950	3,811
’24	821	828	866	835	3,350
’23	660	788	826	718	2,992
’22	662	778	715	671	2,826
’21	585	661	675	673	2,594

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	(10)	—	—	—	—
’26	171	169	118	149	607
’25	108	104	74	259	545
’24	137	214	57	137	545
’23	84	112	278	242	716
’22	(46)	68	233	115	370
’21	144	130	61	153	488

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	(23)	—	—	—	—
’26	53	61	43	58	215
’25	27	24	(25)	131	157
’24	(11)	174	3	64	230
’23	(24)	74	242	195	487
’22	(90)	12	174	67	163
’21	119	93	(4)	109	317

Fiscal quarters ending in the months shown.

EPS $

	Jun	Sep	Dec	Mar	Year
’26	0.06	—	—	—	—
’26	0.20	0.19	0.16	(0.01)	0.55
’25	0.20	0.04	0.20	0.22	0.79
’24	0.21	0.21	0.20	0.19	0.80
’23	0.18	0.16	0.18	0.14	0.66
’22	0.09	0.16	0.11	0.01	0.37
’21	0.09	0.12	0.00	0.06	0.31

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	5.97	5.63	6.93	6.67	11.51	9.58	10.23	13.43	12.26	11.36	Analyst estimates 2027–2029 Powerpack
	High	9.39	7.99	8.56	14.70	15.10	13.07	14.63	16.89	16.17	15.67
People
People	Employees	22,671	23,524	21,966	21,650	22,739	24,795	25,863	27,048	27,811	27,527
	Revenue/emp, $m	0.10	0.09	0.10	0.11	0.11	0.11	0.12	0.12	0.14	0.13
Income, $m
Income, $m	Revenue	2,171	2,181	2,225	2,316	2,594	2,826	2,992	3,350	3,811	3,580
	Gross margin, %	55.64	53.74	54.25	53.84	54.32	53.11	56.68	58.60	58.51	52.77
	EBT	226	220	325	239	361	426	734	862	900	584
	EBT margin, %	10.41	10.09	14.61	10.32	13.92	15.07	24.53	25.73	23.62	16.31
	Net income	186	151	272	259	236	311	548	668	671	452
	Depreciation	174	180	176	165	175	156	154	178	200	220
Per share, $
Per share, $	Revenue	2.61	2.63	2.68	2.79	3.13	3.41	3.60	4.03	4.58	4.30
	Earnings	0.22	0.18	0.33	0.31	0.31	0.37	0.66	0.80	0.79	0.55
	Cash flow	0.40	0.33	0.50	0.48	0.59	0.45	0.86	0.66	0.65	0.73
	Capex	(0.76)	(0.20)	(0.11)	(0.09)	(0.21)	(0.25)	(0.28)	(0.38)	(0.47)	(0.47)
	Free cash flow	(0.36)	0.13	0.39	0.39	0.38	0.20	0.59	0.28	0.19	0.26
	Book value	2.30	2.34	2.44	2.48	2.85	3.03	3.38	4.05	4.74	4.87
	Shares, m	833	829	830	829	829	829	830	832	833	832
Valuation, ×
Valuation, ×	P/E	36.83	35.22	25.19	24.60	43.04	29.88	17.10	18.30	19.98	25.79
	P/S	3.08	2.46	3.02	2.89	3.93	3.27	3.16	3.67	2.88	3.22
	P/B	3.50	2.76	3.32	3.25	4.30	3.68	3.36	3.66	2.78	2.84
	EV/Sales	3.30	2.67	3.11	2.86	3.90	3.21	2.96	3.45	2.85	3.19
	EV/FCF	(23.96)	53.45	21.36	20.70	31.88	55.73	18.18	50.29	69.10	53.09
Cash, $m
Cash, $m	Operating cash flow	332	277	415	396	488	370	716	545	545	607
	Capex	(631)	(168)	(91)	(76)	(171)	(207)	(229)	(315)	(388)	(392)
	Free cash flow	(299)	109	324	320	317	163	487	230	157	215
Balance, $m
Balance, $m	Working capital	237	614	793	763	887	1,158	1,474	1,824	1,401	1,432
	Total debt	758	778	555	293	414	446	164	241	547	824
	Net debt	474	453	192	(63)	(76)	(164)	(603)	(738)	(138)	(114)
	Shareholders’ equity	1,913	1,942	2,027	2,056	2,366	2,511	2,810	3,366	3,947	4,054
Returns, %
Returns, %	ROA	5.70	4.41	8.09	8.17	7.03	8.30	14.09	15.60	12.72	7.63
	ROIC	5.45	4.78	8.51	13.64	12.25	10.36	19.68	19.31	13.82	8.55
	ROE	9.66	7.83	13.70	12.69	10.68	12.76	20.60	21.63	18.13	11.40

Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
VTRS Viatris Inc.	$20.9B	— (loss-making)	61.1×	+4.88% (above 0%: growing)	n/m	+101.08% (above 0%: growing)	38.77%	0.17%	Compare
NBIX Neurocrine Biosciences, Inc.	$13.9B	19.2×	30.5×	+39.49% (above 0%: growing)	+31.19% (above 0%: growing)	+43.69% (above 0%: growing)	97.58%	15.80%	Compare
ELAN Elanco Animal Health Incorporated	$11.8B	— (loss-making)	278×	+10.23% (above 0%: growing)	+450.00% (above 0%: growing)	+35.56% (above 0%: growing)	58.33%	7.97%	Compare
RDY Dr. Reddy's Laboratories Ltd	$10.7B	32.9×	24.3×	−14.44% (below 0%: shrinking)	−70.00% (below 0%: shrinking)	−143.40% (below 0%: shrinking)	46.54%	4.81%
HIMS Hims & Hers Health, Inc.	$6.9B	— (loss-making)	— (loss-making)	+38.25% (above 0%: growing)	n/m	+5.09% (above 0%: growing)	63.83%	(12.90%)	Compare
ALKS Alkermes plc	$6.7B	102×	— (loss-making)	+26.97% (above 0%: growing)	−99.43% (below 0%: shrinking)	+1.13% (above 0%: growing)	80.22%	3.70%	Compare
LNTH Lantheus Holdings, Inc.	$6.5B	23.7×	25.3×	+2.68% (above 0%: growing)	0.00%	+13.55% (above 0%: growing)	62.30%	25.82%	Compare
KNSA Kiniksa Pharmaceuticals International, plc	$6.2B	73.4×	38.7×	+55.36% (above 0%: growing)	+37.50% (above 0%: growing)	+66.63% (above 0%: growing)	90.32%	11.16%	Compare
AMRX AMNEAL PHARMACEUTICALS, INC.	$6.2B	38.4×	51.6×	+9.89% (above 0%: growing)	+157.14% (above 0%: growing)	−351.41% (below 0%: shrinking)	42.01%	16.30%	Compare
Median of peers	$6.8B	38.4×	45.2×	+18.60%	+34.35%	+24.56%	63.06%	9.57%

All 86 Drug Manufacturers Specialty & Generic stocks →